These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29064651)

  • 21. Clinical efficacy of transcutaneous tibial nerve stimulation (TTNS) versus sham therapy (part I) and TTNS versus percutaneous tibial nerve stimulation (PTNS) (part II) on the short term in children with the idiopathic overactive bladder syndrome: protocol for part I of the twofold double-blinded randomized controlled TaPaS trial.
    Ghijselings L; Renson C; Van de Walle J; Everaert K; Spinoit AF
    Trials; 2021 Apr; 22(1):247. PubMed ID: 33810804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome.
    Rostaminia G; Chang C; Pincus JB; Sand PK; Goldberg RP
    Int Urogynecol J; 2019 Oct; 30(10):1735-1745. PubMed ID: 30498931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy.
    Pincus J; Rostaminia G; Chang C; Gafni-Kane A; Goldberg RP
    Neurourol Urodyn; 2019 Aug; 38(6):1676-1684. PubMed ID: 31107570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder.
    Iyer S; Laus K; Rugino A; Botros C; Lozo S; Botros SM; Goldberg R; Tomezsko J; Gafni-Kane A; Wroblewski K; Sand P
    Int Urogynecol J; 2019 Aug; 30(8):1253-1259. PubMed ID: 30467763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
    Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of idiopathic overactive bladder in women: Transcutaneous tibial nerve stimulation alone versus combined with pelvic floor muscle training].
    Baati R; Balhi S; Saadi A; Kraiem R; Kennou B; Ayed H; Chebil M
    Prog Urol; 2020 Dec; 30(17):1126-1133. PubMed ID: 32682849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
    Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
    World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial.
    Lashin AM; Eltabey NA; Wadie BS
    Int Urol Nephrol; 2021 Dec; 53(12):2459-2467. PubMed ID: 34601705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
    Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results.
    Canbaz Kabay S; Kabay S; Mestan E; Cetiner M; Ayas S; Sevim M; Ozden H; Karaman HO
    Neurourol Urodyn; 2017 Jan; 36(1):104-110. PubMed ID: 26352904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome.
    Gordon T; Merchant M; Ramm O; Patel M
    Female Pelvic Med Reconstr Surg; 2021 Jul; 27(7):444-449. PubMed ID: 32649325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder.
    Tudor KI; Seth JH; Liechti MD; Ochulor J; Gonzales G; Haslam C; Fox Z; Pakzad M; Panicker JN
    Clin Auton Res; 2020 Feb; 30(1):61-67. PubMed ID: 30074101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis.
    Burton C; Sajja A; Latthe PM
    Neurourol Urodyn; 2012 Nov; 31(8):1206-16. PubMed ID: 22581511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis.
    Majdinasab N; Orakifar N; Kouti L; Shamsaei G; Seyedtabib M; Jafari M
    Front Neurosci; 2023; 17():1107886. PubMed ID: 36895417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.
    Moossdorff-Steinhauser HF; Berghmans B
    Neurourol Urodyn; 2013 Mar; 32(3):206-14. PubMed ID: 22907807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation.
    Bianchi D; Iacovelli V; Parisi I; Petta F; Gaziev G; Topazio L; Bove P; Vespasiani G; Finazzi Agrò E
    Minerva Urol Nephrol; 2021 Apr; 73(2):260-264. PubMed ID: 31487975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence in Percutaneous Tibial Nerve Stimulation Treatment for Overactive Bladder Syndrome is Best Predicted by Patient Global Impression of Improvement Rather Than Symptom-Specific Improvement.
    Brandon C; Oh C; Brucker BM; Rosenblum N; Ferrante KL; Smilen SW; Nitti VW; Pape DM
    Urology; 2021 Feb; 148():93-99. PubMed ID: 33358753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
    Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
    J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.